Anti-angiogenic therapy in the treatment of advanced renal cell cancer.

RE Board; FC Thistlethwaite; RE. Hawkins

Anti-angiogenic therapy in the treatment of advanced renal cell cancer.

RE Board
, FC Thistlethwaite
, RE. Hawkins

Research output: Contribution to journal › Article › peer-review

Abstract

Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.

Original language	English
Journal	Cancer Treatment Reviews
Publication status	Published - Feb 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{bed238ca35df48ab8b57e77b27564b2c,

title = "Anti-angiogenic therapy in the treatment of advanced renal cell cancer.",

abstract = "Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.",

author = "RE Board and FC Thistlethwaite and RE. Hawkins",

year = "2006",

month = feb,

language = "English",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Co. Ltd",

}

TY - JOUR

T1 - Anti-angiogenic therapy in the treatment of advanced renal cell cancer.

AU - Board, RE

AU - Thistlethwaite, FC

AU - Hawkins, RE.

PY - 2006/2

Y1 - 2006/2

N2 - Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.

AB - Metastatic renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy agents. The majority of tumours are associated with inactivation of the von Hippel-Lindau gene and subsequent overexpression of proangiogenic factors, including vascular endothelial growth factor (VEGF). Drugs targeting these pathways have undergone clinical testing in renal cell cancer with encouraging results. This type of therapy is set to revolutionise the treatment of renal cell cancer and this review outlines recent evidence from clinical trials investigating the most promising of these agents.

M3 - Article

SN - 0305-7372

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Anti-angiogenic therapy in the treatment of advanced renal cell cancer.

Abstract

UN SDGs

Fingerprint

Cite this